TG Therapeutics, Inc. develops and commercializes therapies for the treatment of multiple sclerosis (MS). Its primary product, BRIUMVI (ublituximab), is indicated for the treatment of relapsing forms of MS in adults. The company focuses on advancing its pipeline of therapies targeting B-cell mediated diseases, primarily serving patients with MS. TG Therapeutics operates in the biopharmaceutical sector, primarily in the United States.
